-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on NovoCure, Lowers Price Target to $34

Benzinga·04/23/2025 16:20:54
Listen to the news
Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $42 to $34.